Comparative Pharmacology
Head-to-head clinical analysis: CRYSELLE versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSELLE versus PORTIA 21.
CRYSELLE vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cryselle is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin release, primarily through estrogenic and progestogenic effects on the hypothalamic-pituitary axis. It also increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 16-36 h), with clinical significance for once-daily dosing.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Renal (50% as metabolites, 20% unchanged), fecal (30%), with enterohepatic recirculation.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive